CUSIP 019770106 · who reports it, how much, and how much it matters to them
20 of the 720 hedge fund managers we track reported shares of Allogene Therapeutics, Inc. (Nasdaq: ALLO) on Form 13F for 30 June 2026. Between them they reported USD 127m. The largest position belongs to Sio Capital Management, at USD 28m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Sio Capital Management4 funds on PPLI.com | USD 28m | 4.6% |
| 2 | Citadel Advisors32 funds on PPLI.com | USD 21m | 0.0% |
| 3 | Two Sigma Investments35 funds on PPLI.com | USD 16m | 0.0% |
| 4 | Marshall Wace LLP84 funds on PPLI.com | USD 11m | 0.0% |
| 5 | Millennium Management6 funds on PPLI.com | USD 10m | 0.0% |
| 6 | D. E. Shaw & Co.15 funds on PPLI.com | USD 9.8m | 0.0% |
| 7 | Renaissance Technologies13 funds on PPLI.com | USD 8m | 0.0% |
| 8 | Walleye Capital8 funds on PPLI.com | USD 6.8m | 0.0% |
| 9 | RTW Investments2 funds on PPLI.com | USD 6.8m | 0.1% |
| 10 | Dafna Capital Management6 funds on PPLI.com | USD 4.2m | 0.8% |
| 11 | Boxer Capital Management1 fund on PPLI.com | USD 3.1m | 0.2% |
| 12 | Voleon Capital Management13 funds on PPLI.com | USD 1m | 0.0% |
| 13 | Squarepoint Ops7 funds on PPLI.com | USD 502,000 | 0.0% |
| 14 | Partners Capital Investment Group, LLP26 funds on PPLI.com | USD 336,000 | 0.0% |
| 15 | Graham Capital Management18 funds on PPLI.com | USD 238,000 | 0.0% |
| 16 | Engineers Gate Manager1 fund on PPLI.com | USD 205,000 | 0.0% |
| 17 | Rangeley Capital6 funds on PPLI.com | USD 128,000 | 0.1% |
| 18 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 110,000 | 0.0% |
| 19 | Brevan Howard Capital Management39 funds on PPLI.com | USD 81,157 | 0.0% |
| 20 | BBR Partners8 funds on PPLI.com | USD 60,220 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Sio Capital Management | USD 28m | 4.6% |
| 2 | Dafna Capital Management | USD 4.2m | 0.8% |
| 3 | Boxer Capital Management | USD 3.1m | 0.2% |
| 4 | Rangeley Capital | USD 128,000 | 0.1% |
| 5 | RTW Investments | USD 6.8m | 0.1% |
| 6 | Walleye Capital | USD 6.8m | 0.0% |
| 7 | Voleon Capital Management | USD 1m | 0.0% |
| 8 | Two Sigma Investments | USD 16m | 0.0% |
| 9 | Partners Capital Investment Group, LLP | USD 336,000 | 0.0% |
| 10 | Renaissance Technologies | USD 8m | 0.0% |
Allogene Therapeutics, Inc. trades under the symbol ALLO on the Nasdaq. Its CUSIP, the code used on Form 13F, is 019770106.
20 of the 720 hedge fund managers PPLI.com tracks reported Allogene Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Sio Capital Management (USD 28m), Citadel Advisors (USD 21m), Two Sigma Investments (USD 16m), Marshall Wace LLP (USD 11m) and Millennium Management (USD 10m).
20 managers in our coverage reported it, and between them they run 354 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Sio Capital Management, where the position was 4.6% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Allogene Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.